No Data
No Data
Boundless Bio Inc. Shifts Corporate Updates to IR Website
Boundless Bio, Inc. Q1 Loss Climbs
Boundless Bio | 10-Q: Quarterly report
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD
Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev
No Data